GlassScriptPhysician profile
Christine Morris
NPI 1740649771
$7,352.11
in general payments reported to CMS, 2019-2025
35 companies · $1,304 in 2025
The $1,304 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.94 · 2020: $378 · 2021: $847 · 2022: $1,022 · 2023: $1,715 · 2024: $2,075 · 2025: $1,304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,073 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,073.38 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,156.56 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,060.52 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $951.95 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $796.53 | 2019-2025 | |
| Lilly USA, LLC | $626.20 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $540.17 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $197.52 | 2022-2024 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $188.10 | 2023-2024 | |
| Abbott Laboratories | $172.14 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Axsome Therapeutics, INC. | $168.69 | 2023-2025 | Auvelity, Symbravo |
| Shield Therapeutics INC | $157.60 | 2023-2025 | Accrufer |
| Sumitomo Pharma America, INC. | $150.66 | 2024-2025 | Gemtesa |
| Exact Sciences Corporation | $149.43 | 2023-2025 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $126.45 | 2020-2025 | Nexletol |
| Novartis Pharmaceuticals Corporation | $122.14 | 2022-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $101.29 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $98.42 | 2023-2024 | Spravato |
| Astellas Pharma US INC | $80.25 | 2024-2025 | Veozah |
| Merck Sharp & Dohme LLC | $76.07 | 2020-2024 | Gardasil 9, Capvaxive, Gardasil |
| Inspire Medical Systems, INC. | $71.01 | 2025 | Inspire |
| Currax Pharmaceuticals LLC | $48.33 | 2024-2025 | Contrave |
| Allergan, INC. | $46.11 | 2021-2022 | |
| Boston Scientific Corporation | $40.73 | 2025 | General - Pain Management |
| Sanofi-Aventis U.S. LLC | $27.90 | 2021 | |
| Amgen INC. | $27.19 | 2023 | Otezla, Repatha |
| Actelion Pharmaceuticals US, INC. | $23.60 | 2024 | Uptravi, Opsumit |
| Vivus LLC | $21.79 | 2024 | Qsymia |
| Dynavax Technologies Corporation | $20.98 | 2024 | Heplisav-B |
| Dexcom, INC. | $17.59 | 2023 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $17.43 | 2025 | Rexulti |
| Ethicon US, LLC | $14.98 | 2022 | |
| Medtronic, INC. | $14.68 | 2024 | Venaseal |
| Scynexis, INC. | $13.97 | 2022 | |
| Arbor Pharmaceuticals, INC. | $13.77 | 2021 | |
| Genentech USA, INC. | $11.36 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christine Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.